Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 153 participants.

Also called NCT06376916

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 153 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06376916
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06376916. Randomized; double masking; primary purpose treatment. Start 2024-10-07 (actual); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
Acronym
ATRIUM
Condition
Tachycardia Atrial
Condition
Atrial Flutter With Rapid Ventricular Response
Intervention (Drug)
Magnesium Sulfate 2 G
Intervention (Drug)
Magnesium Sulfate 4 G
Intervention (Drug)
Saline
Lead sponsor
Wake Forest University Health Sciences (class: other)

Record details

Record id
cardio:ct-nct06376916
Content hash
019233c5548fde329928e3b06ea322d4ad119e33cb05f3d3bdb8ad83d057666f